Generic Medicine Info
Indications and Dosage
Parkinson's disease
Adult: Monotherapy: 150-250 mg daily given in 3-5 divided doses. In combination with levodopa therapy: 50-150 mg daily. Dose must be achieved gradually, increase by 50 mg every 3 days. Dosing should be reduced gradually until complete discontinuation of therapy. Dosage recommendations may vary between countries (refer to detailed product guidelines).
Should be taken with food. Take at the end of a main meal.
Acute MI, cardiogenic shock. Concurrent use with antiemetic neuroleptics.
Special Precautions
Avoid abrupt withdrawal. Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Neuroleptic malignant syndrome (abrupt discontinuation); impulse control disorders (e.g. pathologic gambling, compulsive buying, binge or compulsive eating, increased libido, hypersexuality, other pathologic urges), abnormal behaviour (e.g. aggression, confusion, agitation), exacerbation of psychotic disorders (e.g. hallucination, delusion, delirium), dyskinesia, peripheral oedema, sleep disorders (e.g. sudden sleep onset or somnolence), orthostatic hypotension, falls (particularly in the elderly).
Cardiac disorders: Syncope.
Gastrointestinal disorders: Nausea, vomiting, flatulence.
General disorders and administration site conditions: Malaise.
Nervous system disorders: Dizziness.
Vascular disorders: Hypotension.
Patient Counseling Information
This drug may cause somnolence or episodes of sudden sleep onset, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure at the start of therapy; onset of impulse control disorders regularly.
Symptoms: Arterial hypotension or hypertension, nausea and vomiting. Management: Symptomatic treatment.
Drug Interactions
Increased risk of sedation with sedatives. Therapeutic effects of piribedil may be diminished by tetrabenazine.
Potentially Fatal: May cause reciprocal antagonism when taken with anti-emetic neuroleptics; use an anti-emetic without extrapyramidal activity.
Food Interaction
Enhanced sedative effects with alcohol.
Mechanism of Action: Piribedil is a dopamine agonist that stimulates dopamine D2 and D3 receptors and the cerebral dopamine pathways.
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1 hour.
Metabolism: Metabolised into hydroxylated and dihydroxylated derivatives.
Excretion: Via urine (68% as metabolites); bile (25%). Elimination half-life: 1.7 hours (1st phase); 6.9 hours (2nd phase).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4850, Piribedil. https://pubchem.ncbi.nlm.nih.gov/compound/Piribedil. Accessed July 27, 2021.

Store below 30°C.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BC08 - piribedil ; Belongs to the class of dopamine agonists. Used in the management of Parkinson's disease.
Anon. Piribedil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/07/2021.

Buckingham R (ed). Piribedil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/07/2021.

Trivastal Retard 50 (Servier Philippines, Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 05/07/2021.

Trivastal Retard 50 mg Sustained-Release Coated Tablets (Servier Malaysia Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 05/07/2021.

Disclaimer: This information is independently developed by MIMS based on Piribedil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in